These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 18078308)

  • 1. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
    Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
    Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
    Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
    Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
    Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
    J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation.
    Youn YS; Chae SY; Lee S; Kwon MJ; Shin HJ; Lee KC
    Eur J Pharm Biopharm; 2008 Mar; 68(3):667-75. PubMed ID: 17904340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent.
    Lee KC; Chae SY; Kim TH; Lee S; Lee ES; Youn YS
    Regul Pept; 2009 Jan; 152(1-3):101-7. PubMed ID: 18951927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice.
    Youn YS; Jeon JE; Chae SY; Lee S; Lee KC
    Diabetes Obes Metab; 2008 Apr; 10(4):343-6. PubMed ID: 18034839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal formulations of glucagon-like peptide-1: improved bioavailability and anti-diabetic effect.
    Hanato J; Kuriyama K; Mizumoto T; Debari K; Hatanaka J; Onoue S; Yamada S
    Int J Pharm; 2009 Dec; 382(1-2):111-6. PubMed ID: 19698772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice.
    Lee S; Youn YS; Lee SH; Byun Y; Lee KC
    Diabetologia; 2006 Jul; 49(7):1608-11. PubMed ID: 16586064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N; McClean PL; Flatt PR
    J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity.
    Ueda T; Tomita K; Notsu Y; Ito T; Fumoto M; Takakura T; Nagatome H; Takimoto A; Mihara S; Togame H; Kawamoto K; Iwasaki T; Asakura K; Oshima T; Hanasaki K; Nishimura S; Kondo H
    J Am Chem Soc; 2009 May; 131(17):6237-45. PubMed ID: 19361194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
    Nagakura T; Yasuda N; Yamazaki K; Ikuta H; Tanaka I
    Metabolism; 2003 Jan; 52(1):81-6. PubMed ID: 12524666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA
    Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newly approved and promising antidiabetic agents.
    Combettes M; Kargar C
    Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1.
    Lee SH; Lee S; Youn YS; Na DH; Chae SY; Byun Y; Lee KC
    Bioconjug Chem; 2005; 16(2):377-82. PubMed ID: 15769092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
    Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
    Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers.
    Chae SY; Chun YG; Lee S; Jin CH; Lee ES; Lee KC; Youn YS
    J Pharm Sci; 2009 Apr; 98(4):1556-67. PubMed ID: 18704955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
    Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC
    J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.